Upload
spa718
View
1.394
Download
0
Embed Size (px)
Citation preview
Department of Hematology Sheng Jing Hospital of China Medical University
Wang Hong-tao MD & PhD
1
2Brchireddy P, et al. Nat Rev Cancer. 2015;15(4):201-15.
3James N, et al. Nat Rev Clin Oncol. 2013;10:267-76.
4James N, et al. Nat Rev Clin Oncol. 2013;10:267-76.
A Rambaldi, et al. Leukemial. 2015;29:1-10.5
6
7
CAR-T therapy in our centerDisease
LymphomaTarget antigen
CD19Vector
RetrovirusChemotherapy administered before cell
infusionFludarabine and cyclophosphamide
8
CAR-T therapy in our centerPatie
ntGende
r Age (year
s)Diagnosis
Number of prior
therapies
Number of CAR-T
cells infused
Response (duration in months after CAR-T cell infusion)
1 Female 55 DLBCL 10 25×107 PR (1)
2a* Female 30 DLBCL 11 6.6×107 PR (3)
2b* Female 30 DLBCL 11 5×107 SD (9)
3a* Male 41 DLBCL 11 18×107 PR (1)
3b* Male 41 DLBCL 11 19.6×107 CR (5)
4 Male 10 Burkitt’s Lymphoma 8 7×107 NE
5 Female 62 DLBCL 10 7.6×107 PR (2)
* Patient 2 and 3 were treated twice.Abbreviations: CAR, chimeric antigen receptor; DLBCL, diffuse large B cell lymphoma; PR, partial remission; CR, complete remission; NE, not evaluable for malignancy response because the patient died with sepsis.
Clinical index
9
10
Images
Cytokine Release Syndrome
11
57.15% (4/7)Fever Neurologic toxicity (Patient 1)
PreventionTNF α antagonistCRRT?
Cytokines
12
Cytokines
13
NK cells and B cells
14
T cells
15
Thanks !
16
2015.8.28